54162-3 |
Cytoplasmic Ab pattern.PL-7+PL-12 |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Cytoplasmic Ab pattern.PL-7+PL-12 [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Pattern suggestive of PL-7/PL-12-antibody: 1:320. |
|
|
|
|
|
SERO |
|
54162-3 |
|
IF |
|
|
Both |
|
|
|
0 |
CA Pat PL-7+PL-12 Titr Ser IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; CA Pat; CA Pat PL-7+PL-12; Cytopl; Cytoplas; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; PL12; PL7; Point in time; Random; Serology; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.27 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
54163-1 |
Cytomegalovirus DNA |
NCnc |
Urine |
Pt |
Qn |
Probe.amp.tar detection limit = 200 copies/mL |
|
ACTIVE |
Cytomegalovirus DNA [#/volume] (viral load) in Urine by Probe and target amplification method detection limit = 200 copies/ml |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
54163-1 |
|
Probe.amp.tar detection limit = 200 copies/mL |
|
|
Both |
|
|
|
0 |
CMV DNA # Ur NAA DL=200 |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; CMV; Cnt; Count; Count/volume; CT; Cytomegalo virus; Cytomgal; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HHV-5; Human Herpesvirus-5; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA DL=200; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; UA; UR; Urn; Viral load |
2.7 |
2.27 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
54164-9 |
Cytomegalovirus immediate-early Ag |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Cytomegalovirus immediate-early Ag [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
54164-9 |
|
|
|
|
Both |
|
|
|
0 |
CMV IE Ag Bld Ql |
|
|
|
N |
|
Antigen; Antigens; Blood; CMV; CMV IE; Cytomegalo virus; Cytomgal; EA; HHV-5; Human Herpesvirus-5; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
54165-6 |
Tumor necrosis factor binding protein |
ACnc |
Ser |
Pt |
Qn |
|
|
DISCOURAGED |
Tumor necrosis factor binding protein [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
54165-6 |
|
|
|
|
Both |
|
|
|
0 |
TBP-1 Ser-aCnc |
|
|
|
N |
|
Arbitrary concentration; Bind; Chemistry; Fac; Fact; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random; Serum; SR; TBP1; TBP-1; TNF |
2.69 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54166-4 |
Cefoperazone+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefoperazone+Sulbactam [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54166-4 |
|
|
|
|
Both |
|
|
|
0 |
Cefoperazone+Sulbac Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefobid; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54167-2 |
Cefoperazone+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Cefoperazone+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54167-2 |
|
MIC |
|
|
Both |
|
|
|
0 |
Cefoperazone+Sulbac Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefobid; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54168-0 |
Cefoperazone+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cefoperazone+Sulbactam [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54168-0 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Cefoperazone+Sulbac Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefobid; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54169-8 |
Thiamphenicol |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Thiamphenicol [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54169-8 |
|
|
|
|
Both |
|
|
|
0 |
Thiamphenicol Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
5417-1 |
CD102 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD102 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5417-1 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD102 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; ICAM-2; intercellular adhesion; Leukocytes; Molecule-2; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54170-6 |
Imipenem+EDTA |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Imipenem+EDTA [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54170-6 |
|
|
|
|
Both |
|
|
|
0 |
Imipenem+EDTA Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Imipeneum; Imp; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Primaxin; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54171-4 |
Imipenem+EDTA |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Imipenem+EDTA [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54171-4 |
|
MIC |
|
|
Both |
|
|
|
0 |
Imipenem+EDTA Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Imipeneum; Imp; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Primaxin; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54172-2 |
Imipenem+EDTA |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Imipenem+EDTA [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54172-2 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Imipenem+EDTA Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Imipeneum; Imp; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Primaxin; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54173-0 |
Arbekacin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Arbekacin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54173-0 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Arbekacin Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; Habekacin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54174-8 |
Cefmenoxime |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cefmenoxime [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54174-8 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Cefmenoxime Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Bestcall; Cefmax; Cefmenoxim; Cemix; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tacef |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54175-5 |
Caspofungin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Caspofungin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54175-5 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Caspofungin Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54176-3 |
Caspofungin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Caspofungin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54176-3 |
|
MIC |
|
|
Both |
|
|
|
0 |
Caspofungin Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54177-1 |
Clotrimazole |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Clotrimazole [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54177-1 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Clotrimazole Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54178-9 |
Econazole |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Econazole [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54178-9 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Econazole Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; Ecostatin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Spectazole; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54179-7 |
Itraconazole |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Itraconazole [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54179-7 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Itraconaz Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sporanax; Sporanox; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
5418-9 |
CD103 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD103 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5418-9 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD103 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; HML-1; Human mucosal lymphocyte antigen 1; integrin alphaE chain; ITGAE; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54180-5 |
Miconazole |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Miconazole [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54180-5 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Miconazole Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Micostadin; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54181-3 |
Nitroxoline |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Nitroxoline [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54181-3 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Nitroxoline Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54182-1 |
Para aminosalicylate |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Para aminosalicylate [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54182-1 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
PAS Islt KB |
|
|
|
N |
|
Aminosalicycic; Aminosalycilate; ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; Epusal; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; NA-PAS; Nemasol sodium; p-aminosalicyclic acid; Para aminosalicylic acid; PAS; Point in time; Random; Salf-pas; Sodico; Sodium PAS; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Therazid |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54183-9 |
Rifabutin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Rifabutin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54183-9 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Rifabutin Islt KB |
|
|
|
N |
|
Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Mycobutin; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54184-7 |
Thiacetazone |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Thiacetazone [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54184-7 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Thiacetazone Islt KB |
|
|
|
N |
|
Amithiozone; ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Thioacetazone |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |